In conclusion, we identified low-grade endometrial tumors of favorable molecular subtypes to have heightened potential of 11-oxyandrogen metabolism to bioactive 11KT, compared to noncancerous endometrium or high-grade, TP53-alt tumors. The gene discussed is TP53; the disease is endometrium neoplasm.